SNDX Relative Valuation
SNDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SNDX is overvalued; if below, it's undervalued.
Historical Valuation
Syndax Pharmaceuticals Inc (SNDX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -7.77. The fair price of Syndax Pharmaceuticals Inc (SNDX) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 19.66 USD , Syndax Pharmaceuticals Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：19.66
Fair
Undervalued
-10.47
PE
1Y
3Y
5Y
Trailing
Forward
-8.58
EV/EBITDA
Syndax Pharmaceuticals Inc. (SNDX) has a current EV/EBITDA of -8.58. The 5-year average EV/EBITDA is -3.15. The thresholds are as follows: Strongly Undervalued below -16.91, Undervalued between -16.91 and -10.03, Fairly Valued between 3.72 and -10.03, Overvalued between 3.72 and 10.60, and Strongly Overvalued above 10.60. The current Forward EV/EBITDA of -8.58 falls within the Historic Trend Line -Fairly Valued range.
-10.76
EV/EBIT
Syndax Pharmaceuticals Inc. (SNDX) has a current EV/EBIT of -10.76. The 5-year average EV/EBIT is -6.62. The thresholds are as follows: Strongly Undervalued below -22.97, Undervalued between -22.97 and -14.80, Fairly Valued between 1.56 and -14.80, Overvalued between 1.56 and 9.73, and Strongly Overvalued above 9.73. The current Forward EV/EBIT of -10.76 falls within the Historic Trend Line -Fairly Valued range.
5.38
PS
Syndax Pharmaceuticals Inc. (SNDX) has a current PS of 5.38. The 5-year average PS is 354.98. The thresholds are as follows: Strongly Undervalued below -1142.42, Undervalued between -1142.42 and -393.72, Fairly Valued between 1103.69 and -393.72, Overvalued between 1103.69 and 1852.39, and Strongly Overvalued above 1852.39. The current Forward PS of 5.38 falls within the Historic Trend Line -Fairly Valued range.
-22.35
P/OCF
Syndax Pharmaceuticals Inc. (SNDX) has a current P/OCF of -22.35. The 5-year average P/OCF is -7.49. The thresholds are as follows: Strongly Undervalued below -24.93, Undervalued between -24.93 and -16.21, Fairly Valued between 1.23 and -16.21, Overvalued between 1.23 and 9.94, and Strongly Overvalued above 9.94. The current Forward P/OCF of -22.35 falls within the Undervalued range.
-139.84
P/FCF
Syndax Pharmaceuticals Inc. (SNDX) has a current P/FCF of -139.84. The 5-year average P/FCF is -11.49. The thresholds are as follows: Strongly Undervalued below -52.08, Undervalued between -52.08 and -31.79, Fairly Valued between 8.80 and -31.79, Overvalued between 8.80 and 29.10, and Strongly Overvalued above 29.10. The current Forward P/FCF of -139.84 falls within the Strongly Undervalued range.
Syndax Pharmaceuticals Inc (SNDX) has a current Price-to-Book (P/B) ratio of 14.84. Compared to its 3-year average P/B ratio of 4.42 , the current P/B ratio is approximately 235.82% higher. Relative to its 5-year average P/B ratio of 4.13, the current P/B ratio is about 259.09% higher. Syndax Pharmaceuticals Inc (SNDX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -15.56%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -10.98% , the current FCF yield is about -100.00% lower.
14.86
P/B
Median3y
4.42
Median5y
4.13
-18.15
FCF Yield
Median3y
-15.56
Median5y
-10.98
Competitors Valuation Multiple
The average P/S ratio for SNDX's competitors is 3.16, providing a benchmark for relative valuation. Syndax Pharmaceuticals Inc Corp (SNDX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 266.97%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SNDX increased by 49.32% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 12.50M to 45.87M.
The secondary factor is the Margin Expansion, contributed -80.33%to the performance.
Overall, the performance of SNDX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Syndax Pharmaceuticals Inc (SNDX) currently overvalued or undervalued?
What is Syndax Pharmaceuticals Inc (SNDX) fair value?
How does SNDX's valuation metrics compare to the industry average?
What is the current P/B ratio for Syndax Pharmaceuticals Inc (SNDX) as of Dec 05 2025?
What is the current FCF Yield for Syndax Pharmaceuticals Inc (SNDX) as of Dec 05 2025?
What is the current Forward P/E ratio for Syndax Pharmaceuticals Inc (SNDX) as of Dec 05 2025?